Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
SUPERIORITY OF IBUTILIDE (A NEW CLASS-III AGENT) OVER DL-SOTALOL IN CONVERTING ATRIAL-FLUTTER AND ATRIAL-FIBRILLATION
Autore:
VOS MA; GOLITSYN SR; STANGL K; RUDA MY; VANWIJK L; HARRY JD; PERRY KT; TOUBOUL P; STEINBECK G; WELLENS HJJ;
Indirizzi:
UNIV HOSP MAASTRICHT,INST CARDIOVASC RES,DEPT CARDIOL,POB 5800 NL-6202 AZ MAASTRICHT NETHERLANDS CARDIOL RES CTR MOSCOW 121552 RUSSIA HUMBOLDT UNIV BERLIN GERMANY ST CHR ZIEKENHUIS REFAJA STADSKANAAL NETHERLANDS PHARMACIA & UPJOHN INC CRAWLEY W SUSSEX ENGLAND PHARMACIA & UPJOHN INC KALAMAZOO MI 49001 CTR HOSP LYON SUD LYON FRANCE UNIV MUNICH,KLINIKUM GROSSHADERN MUNICH GERMANY
Titolo Testata:
HEART
fascicolo: 6, volume: 79, anno: 1998,
pagine: 568 - 575
SICI:
1355-6037(1998)79:6<568:SOI
Fonte:
ISI
Lingua:
ENG
Soggetto:
SINUS RHYTHM; ANTIARRHYTHMIC AGENTS; SUPRAVENTRICULAR TACHYCARDIA; INTRAVENOUS IBUTILIDE; FLECAINIDE ACETATE; ACUTE CONVERSION; I-KR; ARRHYTHMIAS; EFFICACY; CELLS;
Keywords:
ATRIAL FIBRILLATION; ATRIAL FLUTTER; ANTIARRHYTHMIC AGENTS; IBUTILIDE; SOTALOL;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
36
Recensione:
Indirizzi per estratti:
Citazione:
M.A. Vos et al., "SUPERIORITY OF IBUTILIDE (A NEW CLASS-III AGENT) OVER DL-SOTALOL IN CONVERTING ATRIAL-FLUTTER AND ATRIAL-FIBRILLATION", HEART, 79(6), 1998, pp. 568-575

Abstract

Objective-To compare the efficacy and safety of a single dose of ibutilide, a new class III antiarrhythmic drug, with that of DL-sotalol interminating chronic atrial fibrillation or flutter in haemodynamically stable patients, Design-Double blind, randomised study. Setting-43 European hospitals. Patients-308 patients (mean age 60 years, 70% men, 48% with heart disease) with sustained atrial fibrillation (n = 251) or atrial flutter (n = 57) (duration three hours to 45 days) were randomised to three groups to receive a 10 minute infusion of 1 mg ibutilide (n = 99), 2 mg ibutilide (n = 106), or 1.5 mg/kg DL-sotalol (n = 103). Infusion was discontinued at termination of the arrhythmia. Main outcome measure-Successful conversion of atrial fibrillation or flutter,defined as termination of arrhythmia within one hour of treatment, Results-Both drugs were more effective against atrial flutter than against atrial fibrillation. ibutilide was superior to DL-sotalol for treating atrial flutter (70% and 56% v 19%), while the high dose of ibutilide was more effective for treating atrial fibrillation than DL-sotalol(44% v 11%) and the lower dose of ibutilide (44% v 20%, p < 0.01), The mean (SD) time to arrhythmia termination was 13 (7) minutes with 2 mg ibutilide, 19 (15) minutes with 1 mg ibutilide, and 25 (17) minutes with DL-sotalol. In all patients, the duration of arrhythmia before treatment was a predictor of arrhythmia termination, although this was less obvious in the group that received 2 mg ibutilide, This dose converted almost 48% of atrial fibrillation that was present for more than 30 days. Concomitant use of digitalis or nifedipine and prolongation of the QTc interval were not predictive of arrhythmia termination. Bradycardia (6.5%) and hypotension (3.7%) were more common side effects with. DL-sotalol. Of 211. patients given ibutilide, two (0.9%) who received the higher dose developed polymorphic ventricular tachycardia, oneof whom required direct current cardioversion. Conclusion-Ibutilide (given in 1 or 2 mg doses over 10 minutes) is highly effective for rapidly terminating persistent atrial fibrillation or atrial flutter. Thisnew class III drug, under monitored conditions, is a potential alternative to currently available cardioversion options.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 29/10/20 alle ore 21:39:06